Esmd-2076, a CASI targeted drug, for the treatment of triple negative breast cancer

Casi pharmaceutical is committed to introducing, developing and commercializing innovative drugs, aiming at the tumor and other unmet medical needs, facing the global market and focusing on the Greater China market Today, it announced that it has launched its targeted drug enmd-2076 in the second phase of the international multi center clinical trial for the treatment of triple negative breast cancer in China The Cancer Hospital of the Chinese Academy of Medical Sciences is the leading unit of the study The phase II international multicenter clinical trial is an extension of the ongoing phase II clinical trials at the University of Colorado cancer center and the University of Indiana cancer centers Melvin and brensimon The safety and efficacy of enmd-2076 in the treatment of Chinese patients will be evaluated At the same time, the relationship between disease targeting biomarkers and clinical efficacy of drugs will be analyzed Dr Chen Zhaorong, chief medical officer of CASI pharmaceutical, said: we are very pleased to launch the first clinical trial of enmd-2076 in China and look forward to seeing that it will benefit Chinese patients The clinical research data of China will supplement and verify the data of international multicenter clinical trials in the United States at present, and provide new clinical observation results for its sensitivity and specificity to Chinese patients, and provide valuable information and data for us to continue the development of anti-tumor indications of enmd-2076 Dr Ren Keyong, chief executive officer of CASI, said: we are very pleased and grateful to Professor Xu binghe and Cancer Hospital of Chinese Academy of Medical Sciences for participating in and leading our international multicenter clinical trial in China Their rich knowledge and experience in clinical research in the field of solid tumor, especially in the field of breast cancer treatment, as well as their accumulation and achievements in the clinical research of innovative anti-tumor drugs, have a very important guiding significance for the promotion of our clinical trials in China and the development of new anti-tumor drugs in the world The above article is the author's personal opinion and does not represent the position of this website The intellectual property rights of the published content belong to yaozhi.com If you need to reprint, please indicate the source and the link of this article.